Ecnoglutide

Ecnoglutide (XW-003) is a long-acting, cAMP-biased GLP-1 receptor agonist developed by Hangzhou Sciwind Biosciences. "Biased" means it preferentially drives cAMP (G-protein) signaling over β-arrestin recruitment, which its developers argue improves efficacy. In 2026 it became the world's first approved cAMP-biased GLP-1RA, cleared by China's NMPA for type 2 diabetes (30 January 2026, marketed as Xianyida) and then for chronic weight management (6 March 2026). It is not approved by the FDA or EMA; outside China it circulates as a research-use-only compound.

What is Ecnoglutide and why does biased signaling matter?

Ecnoglutide is engineered to bias GLP-1 receptor signaling toward the cAMP pathway, which preclinical and clinical work from its developer links to improved weight-loss efficacy relative to unbiased GLP-1 peptides. Mechanistically it still produces the core GLP-1 effects (insulin secretion, glucagon suppression, appetite reduction) like semaglutide, with the biased-signaling twist as its differentiator.

What does the clinical evidence show?

Ecnoglutide has completed Phase 3 trials in China. In the SLIMMER obesity trial (664 adults with overweight or obesity, 36 sites, 48 weeks), once-weekly ecnoglutide produced mean weight loss of 9.9% at 1.2 mg, 13.3% at 1.8 mg, and 15.4% at 2.4 mg, versus 0.3% on placebo — 15.1% placebo-adjusted at the top dose — with 92.8% of participants on 2.4 mg losing at least 5% of body weight (vs 13.9% on placebo); the full results were published in The Lancet Diabetes & Endocrinology in June 2025. In type 2 diabetes, the published Phase 3 program includes EECOH-1 (monotherapy vs placebo: HbA1c down 2.43 percentage points at 24 weeks on 1.2 mg, with 80.3% reaching HbA1c below 7.0%) and the 52-week head-to-head EECOH-2, an open-label non-inferiority trial against dulaglutide 1.5 mg in patients on metformin, in which ecnoglutide showed greater HbA1c reductions. A head-to-head against semaglutide exists so far only as company-reported interim data, not yet peer-reviewed: in the SLIMMER-UP-SWITCH Phase 2 trial (163 adults, open-label, matched 2.4 mg maintenance doses), Sciwind reported Week-20 interim weight loss of 12.8% for ecnoglutide versus 9.5% for semaglutide, presented as a late-breaking poster at the June 2026 ADA sessions — an interim readout from an ongoing 60-week open-label study, not a published result. Evidence level: Phase 3 (China-based); approved in China, not FDA/EMA. The evidence base is geographically concentrated and newer than the established GLP-1s.

Sources: Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (SLIMMER), Ji L. et al. (co-corresponding Zheng Q., Sciwind; 29 authors — optional, non-blocking: complete list), Lancet Diabetes Endocrinol, 2025; Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial, Zhu D. et al. (optional, non-blocking: complete list), Nat Commun, 2026; Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's NMPA for Adult Type 2 Diabetes, Sciwind Biosciences, via PRNewswire (company release); Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial, He Y. et al. (optional, non-blocking: complete list), Lancet Diabetes Endocrinol, 2025

What are the documented side effects of Ecnoglutide?

In the SLIMMER Phase 3 trial, the most common adverse events were mild-to-moderate gastrointestinal disorders and decreased appetite, occurring mainly during dose escalation — the familiar GLP-1-class profile. No participant developed pancreatitis, medullary thyroid cancer, or severe gallbladder-related adverse events in the trial. Long-term and non-Chinese-population data are still limited (as of August 2026).

Source: Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (SLIMMER), Ji L. et al. (co-corresponding Zheng Q., Sciwind; 29 authors — optional, non-blocking: complete list), Lancet Diabetes Endocrinol, 2025 · Evidence level: phase 3

What is the regulatory status, and how does research-market material differ?

Ecnoglutide is approved in China only: the NMPA cleared it for adult type 2 diabetes on January 30, 2026 (marketed as Xianyida) and for chronic weight management on March 6, 2026 (marketed as Xianweiying), making it the world's first approved cAMP-biased GLP-1 receptor agonist. Pfizer licensed China commercialization rights from Sciwind in February 2026, with Sciwind retaining R&D, manufacturing, and supply. As of August 2026 it is not approved by the FDA, EMA, or any regulator outside China, so material sold outside China (or through research-chemical vendors) is not an approved product for those markets and its identity cannot be assumed. Because the approved product exists only inside China's pharmacy channel, there is no legitimate retail source of Xianyida/Xianweiying outside China — vials sold by research-chemical vendors are a separate, unregulated supply chain with no reference product to compare against. See the risks of the grey-market peptide supply chain. See the legal status guide.

Sources: Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's NMPA for Adult Type 2 Diabetes, Sciwind Biosciences, via PRNewswire (company release); Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's NMPA for Chronic Weight Management, Sciwind Biosciences, via PRNewswire (company release)

Why does vendor verification matter, and how does Peptigrity verify?

As a newer compound with an approval limited to one market, research-market ecnoglutide is a prime candidate for mislabeling — HPLC purity and mass-spec identity are the objective checks. Peptigrity collects independent third-party Certificates of Analysis for ecnoglutide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The trust score weights lab purity and reviews equally (50/50). No independent ecnoglutide lab tests are on file yet (verified August 2026) — for a compound this new, an identity-confirmed, batch-matched COA showing actual peptide content is the only meaningful buyer signal. Track new results at independent ecnoglutide lab tests. See how to read lab results.

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade ecnoglutide sold for laboratory use is not an FDA-approved product. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.

Frequently asked questions